


Supplementary Information:

Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders


Vassilios J. Bezzerides^{1,2}, Aifeng Zhang^{1,5}, Ling Xiao⁵, Bridget Simonson^{1,5}, Santosh A. Khedkar^{1,3}, Shiro Baba⁶, Filomena Ottaviano¹, Stacey Lynch⁴, Katherine Hessler¹, Alan C. Rigby^{1,4}, David Milan⁵, Saumya Das^{1,5*} and Anthony Rosenzweig^{1,5*}.

1. Beth Israel Deaconess Medical Center, Boston, MA.
2. Boston Children's Hospital, Department of Cardiology, Boston, MA.
3. Current address: ChemBio Discovery Solutions, Lexington, MA.
4. Warp Drive Bio Inc., Cambridge, MA.
5. Massachusetts General Hospital, Boston, MA.
6. Graduate School of Medicine Kyoto University, Kyoto City, Japan.

*: These authors contributed equally to the work.



Supplemental Figure 1: Inhibition of SGK1 activity by additional SGK1 inhibitor compound 6410136 in cardiomyocytes



Supplemental Figure 2: Increase in hERG tail currents with SGK1 inhibitor. Representative traces from HEK cells expressing hERG either pre incubated for 5 minutes with **A**. DMSO or **B**. SGK1 inhibitor 5377051. **C**. Combined tail current data from n = 3-4 cells per condition, using voltage protocol as shown in inset in A and measured as indicated.